All News

Machine Learning helps predict RA relapse: data from KURAMA, 210 RA pts (150 achieved remission; 60 relapsed). Using clinical, lab and US findings, ML identified US findings in wrist and MTP predictors of relapse https://t.co/9rhctim4Mh https://t.co/iK3JudOMsC

Links:

Dr. John Cush RheumNow ( View Tweet)
morbidity,covid,heart,lung,brain

Multimorbidity Burden in Rheumatoid Arthritis

d Jack Cush, MD

Crowson and colleagues at the Mayo Clinic have shown that rheumatoid arthritis (RA) patients have a higher prevalence of multimorbidity with as many as 44 different morbidities of interest in RA.

Read Article
ASCORE: Seropositivity Favors Abatacept Drug Survival The ASCORE study evaluated efficacy, safety, and drug retention (durability) of ABA in moderate-to-severe RA and found consistently better ABA durability in those who were seropositive. https://t.co/dLFC3dW4Tv https://t.co/LNCUIQjnGf

Links:

Dr. John Cush RheumNow ( View Tweet)
Methotrexate

Can You Reduce Frequency of Methotrexate Monitoring?

d Jack Cush, MD

Observational research presented at the British Society for Rheumatology meeting suggest that, based on the COVID-19 pandemic experience, reduced frequency of routine lab monitoring in patients receiving weekly methotrexate therapy for rheumatoid arthritis (RA) was not associated with an increase in adverse outcomes.

Read Article
Early inflammatory arthritis pts (n=35,807; 86% White & 5,164 ethnic minority). Whites & minorities were equally seen by rheum <3 wks & started on Rx < 6wks, <inorities had less remission @3 mos (OR 0.79) or recv MTX 1st or steroids(0.68-0.63) https://t.co/rK7GLt5n1X https://t.co/uUwBBCnyGL

Links:

Dr. John Cush RheumNow ( View Tweet)
Making You the Expert of You! (Smart Rules for Patients) You’ve scheduled an appointment with your medical provider - how do you make the most of it? https://t.co/62mTqk4ksL https://t.co/gr7Hvt7EI3

Links:

Dr. John Cush RheumNow ( View Tweet)
RA.Ow02.jpg

ASCORE: Seropositivity Favors Abatacept Drug Survival

d Jack Cush, MD

The ASCORE (Abatacept SubCutaneOus in Routine clinical practicE) study evaluated efficacy, safety, and drug retention (durability) of abatacept (ABA) moderate-to-severe rheumatoid arthritis (RA) and found consistently better ABA durability in those who were seropositive. 

Read Article
Patient,instruction

Making You the Expert of You! (Smart Rules for Patients)

d Jack Cush, MD

You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.

Read Article
Prophylaxis against pneumocystis pneumonia in RA patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry https://t.co/zeDQpP1NEH proph reduced PCP by 3/1000 per yr, 5 pts PCP despite proph, 80% on MTX & 11% cease proph due to AEs!

Links:

Peter Nash drpnash ( View Tweet)

Evobrutinib, selective oral BTK inhibitor, has been studied in >1083 pts in phase 3 RCTs of RA, SLE, MS; shows well tolerated, most common AE ≥5% UTI (9.5%), nasopharyngitis (7.3%), diarrhea (6.2%), transient ^LFTs, SIE rate 2.72/100 PYs https://t.co/NTKYOAHhln https://t.co/oUKCDicjyA

Links:

Dr. John Cush RheumNow ( View Tweet)
Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritis https://t.co/5dXe0AdNzE https://t.co/eS4KdaKBmC

Links:

Dr. John Cush RheumNow ( View Tweet)
An increasing incidence of RA is driven by increasing # of ACPA-negative RA (but not ACPA-positive RA), partly explained by an ageing population (thus making ACPA-negative RA more prevalent in coming years) https://t.co/9vC8aCphKc

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast square

What is JAKne? (5.6.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports, FDA actions, new side effects and changing prevalence of Gout.

Read Article
medical.marijuana

Lack of Research Stymies Uptake of Medical Marijuana for Rheumatic Pain

d Creaky Joints

A new review article from CreakyJoints finds that there has been limited progress in understanding the potential of cannabis based therapies for the treatment of pain associated with rheumatic conditions in the past five years because of a lack of standardization of clinical research and barriers to conducting research due to existing federal and state regulations.

Read Article
Trends in RA Disability, Despite Biologics Disability claims in the U.S. related to RA were just as common in 2015 as in 1999, a gov't researcher found, against expectations that the advent of biologic therapy would have led to a steady decrease. https://t.co/vyyjTbkLN2 https://t.co/D5Eo42P4cw

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 17 homeless RA or PsA pts - less clinic access (80% vs 91%), more ED use (20 vs 5), less DMARDs (43% vs 100%), more steroids (29% vs 0%); 83% unable to work due to health. Greatest need - dental , PT, knee surgery, employment & housing https://t.co/VHnTR0MTkr https://t.co/JDZTELz2qB

Links:

Dr. John Cush RheumNow ( View Tweet)
There is 1.4 million transgender persons in the US. ACP has published a guideline "Care of the Transgender Patient" addressing health disparities, certain cancers, substance abuse, mental health conditions, infections, and chronic diseases. https://t.co/AoBeOzv9YH https://t.co/jKabVELPxH

Links:

Dr. John Cush RheumNow ( View Tweet)
Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritis https://t.co/n1O4g4HpMM https://t.co/ulF1d2gDkG

Links:

Dr. John Cush RheumNow ( View Tweet)
DMARDs,biologics,RA

Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritis

d Jack Cush, MD

Analysis of rheumatoid arthritis (RA) data from the British Society for Rheumatology Biologics Register shows that, even after failing three or more biologic or targeted synthetic DMARDs (b/tsDMARDs), patients may continue to benefit from repeated trials of unused b/tsDMARDs. 

Read Article
Did you miss last night's TNR on RA, improving future therapy? We've got you covered. Listen to the playback here. https://t.co/ci6TZOw3VX https://t.co/31gRUaKbQm

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.